Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous dendritic cell/myeloma fusion vaccine

A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Upon administration, autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous DC/multiple myeloma fusions
DC/MM fusion vaccine
DC/MM fusions
DC/multiple myeloma fusions
DC/plasma cell myeloma fusion
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search